Verrica Pharmaceuticals Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Verrica Pharmaceuticals Inc. (VRCA) reported Revenue from Contract with Customer, Excluding Assessed Tax of $12.70 million for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-12.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2025-08-12
- Verrica Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $12.70M, a 145.35% increase year-over-year.
- Verrica Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $3.44M, a 10.12% decline year-over-year.
- Verrica Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-12-31 was $344.00K, a 82.70% decline year-over-year.
- Verrica Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-09-30 was -$1.78M, a 161.06% decline year-over-year.
- Verrica Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $7.57M, a 47.66% increase from fiscal 2023.
- Verrica Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $5.12M, a 43.27% decline from fiscal 2022.
- Verrica Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $9.03M, a 24.73% decline from fiscal 2021.
- Verrica Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $12.00M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-06-30 | $12.70M 10-Q · filed 2025-08-12 | $16.14M 10-Q · filed 2025-08-12 | $16.48M derived: sum of 3 quarters · filed 2025-08-12 | $14.70M derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | $3.44M 10-Q · filed 2025-05-13 | $3.78M derived: sum of 2 quarters · filed 2025-05-13 | $2.00M derived: sum of 3 quarters · filed 2025-05-13 | $7.18M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-12-31 | $344.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$1.44M derived: sum of 2 quarters · filed 2025-03-11 | $3.74M derived: sum of 3 quarters · filed 2025-08-12 | $7.57M 10-K · filed 2025-03-11 |
| 2024-09-30 | -$1.78M 10-Q · filed 2024-11-05 | $3.40M derived: sum of 2 quarters · filed 2025-08-12 | $7.22M 10-Q · filed 2024-11-05 | $9.21M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-06-30 | $5.18M 10-Q · filed 2025-08-12 | $9.00M 10-Q · filed 2025-08-12 | $10.99M derived: sum of 3 quarters · filed 2025-08-12 | $13.91M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $3.83M 10-Q · filed 2025-05-13 | $5.81M derived: sum of 2 quarters · filed 2025-05-13 | $8.73M derived: sum of 3 quarters · filed 2025-05-13 | $8.91M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $4.91M derived: sum of 2 quarters · filed 2025-03-11 | $5.09M derived: sum of 3 quarters · filed 2025-03-11 | $5.12M 10-K · filed 2025-03-11 |
| 2023-09-30 | $2.92M 10-Q · filed 2024-11-05 | $3.10M derived: sum of 2 quarters · filed 2024-11-05 | $3.14M 10-Q · filed 2024-11-05 | $3.20M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $182.00K 10-Q · filed 2024-08-14 | $219.00K 10-Q · filed 2024-08-14 | $287.00K derived: sum of 3 quarters · filed 2024-08-14 | $8.61M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $37.00K 10-Q · filed 2024-05-13 | $105.00K derived: sum of 2 quarters · filed 2024-05-13 | $8.42M derived: sum of 3 quarters · filed 2024-05-13 | $8.64M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $68.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $8.39M derived: sum of 2 quarters · filed 2024-02-29 | $8.60M derived: sum of 3 quarters · filed 2024-02-29 | $9.03M 10-K · filed 2024-02-29 |
| 2022-09-30 | $8.32M 10-Q · filed 2023-11-09 | $8.53M derived: sum of 2 quarters · filed 2023-11-09 | $8.96M 10-Q · filed 2023-11-09 | $8.96M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $214.00K 10-Q · filed 2023-08-08 | $645.00K 10-Q · filed 2023-08-08 | $645.00K derived: sum of 3 quarters · filed 2023-08-08 | $645.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $431.00K 10-Q · filed 2023-05-09 | $431.00K derived: sum of 2 quarters · filed 2023-05-09 | $431.00K derived: sum of 3 quarters · filed 2023-05-09 | $431.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $0.00 derived: sum of 2 quarters · filed 2023-03-06 | $0.00 derived: sum of 3 quarters · filed 2023-03-06 | $12.00M 10-K · filed 2023-03-06 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-07 | $0.00 derived: sum of 2 quarters · filed 2022-11-07 | $12.00M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-11 | $12.00M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $12.00M 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |